SG10201402236VA - Yeast-based vaccine for inducing an immune response - Google Patents
Yeast-based vaccine for inducing an immune responseInfo
- Publication number
- SG10201402236VA SG10201402236VA SG10201402236VA SG10201402236VA SG10201402236VA SG 10201402236V A SG10201402236V A SG 10201402236VA SG 10201402236V A SG10201402236V A SG 10201402236VA SG 10201402236V A SG10201402236V A SG 10201402236VA SG 10201402236V A SG10201402236V A SG 10201402236VA
- Authority
- SG
- Singapore
- Prior art keywords
- yeast
- inducing
- immune response
- based vaccine
- vaccine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16311—Influenzavirus C, i.e. influenza C virus
- C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76502506P | 2006-02-02 | 2006-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201402236VA true SG10201402236VA (en) | 2014-08-28 |
Family
ID=38345897
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG201100779-6A SG169375A1 (en) | 2006-02-02 | 2007-02-02 | Yeast-based vaccine for inducing an immune response |
SG10201402236VA SG10201402236VA (en) | 2006-02-02 | 2007-02-02 | Yeast-based vaccine for inducing an immune response |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG201100779-6A SG169375A1 (en) | 2006-02-02 | 2007-02-02 | Yeast-based vaccine for inducing an immune response |
Country Status (14)
Country | Link |
---|---|
US (2) | US7736642B2 (en) |
EP (2) | EP1988919A4 (en) |
JP (3) | JP5198290B2 (en) |
KR (2) | KR101492524B1 (en) |
CN (2) | CN104826102A (en) |
AU (1) | AU2007212076B2 (en) |
BR (1) | BRPI0706913A2 (en) |
CA (1) | CA2638815A1 (en) |
IL (2) | IL193196A (en) |
IN (1) | IN2014DN08830A (en) |
MX (1) | MX2008009929A (en) |
SG (2) | SG169375A1 (en) |
TW (2) | TW201412329A (en) |
WO (1) | WO2007092792A2 (en) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7083787B2 (en) * | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
US8343502B2 (en) * | 2002-12-16 | 2013-01-01 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
WO2004058157A2 (en) * | 2002-12-16 | 2004-07-15 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
BRPI0613025A2 (en) * | 2005-07-11 | 2010-12-14 | Globeimmune Inc | composition for reducing resistance to an agent, method for preparing a yeast vehicle and use of the composition |
US20070172503A1 (en) * | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
TW201412329A (en) * | 2006-02-02 | 2014-04-01 | Globeimmune Inc | Yeast-based vaccine for inducing an immune response |
GB0613977D0 (en) | 2006-02-07 | 2006-08-23 | Peptcell Ltd | Peptide sequences and compositions |
WO2007130330A2 (en) * | 2006-05-01 | 2007-11-15 | Technovax, Inc. | Polyvalent influenza virus-like particle (vlp) compositions |
EP1998814A4 (en) * | 2006-05-11 | 2010-06-16 | Novavax Inc | Novel influenza m2 vaccines |
US9511134B2 (en) * | 2006-05-18 | 2016-12-06 | Epimmune Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
CA2676783C (en) * | 2007-02-02 | 2016-04-05 | Globeimmune, Inc. | Improved methods for producing yeast-based vaccines |
JP5579451B2 (en) * | 2007-03-19 | 2014-08-27 | グローブイミューン,インコーポレイテッド | Composition for targeted ablation of avoidance of variability in targeted therapy for cancer |
GB0719526D0 (en) * | 2007-10-05 | 2007-11-14 | Isis Innovation | Compositions and methods |
US20100285050A1 (en) | 2007-10-05 | 2010-11-11 | Isis Innovation Limited | Compositions and Methods |
WO2010036948A2 (en) * | 2008-09-26 | 2010-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Dna prime/inactivated vaccine boost immunization to influenza virus |
KR102019728B1 (en) | 2009-04-17 | 2019-09-09 | 글로브이뮨 | Combination immunotherapy compositions against cancer and methods |
JP2012527232A (en) * | 2009-05-18 | 2012-11-08 | パナセア バイオテック リミテッド | Genetically modified vaccinia Ankara virus (MVA) based influenza universal vaccine |
JP5913103B2 (en) | 2009-09-14 | 2016-04-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate | Combinations comprising yeast-based immunotherapy compositions and methods for screening subjects |
WO2012006561A2 (en) * | 2010-07-08 | 2012-01-12 | New York Medical College | Influenza virus detection and diagnosis |
CN103328002B (en) * | 2010-10-04 | 2020-01-14 | 麻省理工学院 | Hemagglutinin polypeptides and reagents and methods related thereto |
US9173933B2 (en) * | 2010-10-15 | 2015-11-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus Ankara influenza vaccine |
ES2696551T3 (en) * | 2010-12-17 | 2019-01-16 | Globeimmune Inc | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
EP2670430B1 (en) | 2011-01-31 | 2015-04-01 | Baxter International Inc | Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses |
AU2012214394B2 (en) | 2011-02-12 | 2016-08-11 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis B infection |
MX350661B (en) * | 2011-03-17 | 2017-09-13 | Us Health | Yeast-brachyury immunotherapeutic compositions. |
WO2012162342A2 (en) * | 2011-05-23 | 2012-11-29 | The Wistar Institute Of Anatomy And Biology | Influenza vaccines containing modified adenovirus vectors |
US9579377B2 (en) * | 2011-06-14 | 2017-02-28 | Globeimmune, Inc. | Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection |
KR20140047069A (en) * | 2011-06-20 | 2014-04-21 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Computationally optimized broadly reactive antigens for h1n1 influenza |
KR102049928B1 (en) | 2011-08-17 | 2019-11-28 | 글로브이뮨 | Yeast-muc1 immunotherapeutic compositions and uses thereof |
ES2525205T3 (en) * | 2011-11-09 | 2014-12-18 | Werner Lubitz | Vaccine for use in tumor immunotherapy |
DE102011121069A1 (en) | 2011-12-13 | 2013-06-13 | Martin-Luther-Universität Halle-Wittenberg | Vaccination by recombinant yeast by generating a protective humoral immune response against defined antigens |
WO2014003853A1 (en) | 2012-06-26 | 2014-01-03 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
US9744193B2 (en) | 2012-09-06 | 2017-08-29 | Orbis Health Solutions Llc | Tumor lysate loaded particles |
JP5954079B2 (en) | 2012-09-25 | 2016-07-20 | ソニー株式会社 | Culture observation apparatus and culture observation method |
AU2013359469B2 (en) * | 2012-12-10 | 2019-05-16 | Seattle Biomedical Research Institute | Cell-free biofragment compositions and related systems, devices, and methods |
KR20150128900A (en) * | 2013-03-15 | 2015-11-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Vaccines having an antigen and interleukin-23 as an adjuvant |
EP2976100B1 (en) | 2013-03-19 | 2020-07-01 | Globeimmune, Inc. | Yeast-based immunotherapy for chordoma |
TWI728239B (en) | 2013-03-26 | 2021-05-21 | 美商環球免疫公司 | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
JP2014210747A (en) * | 2013-04-19 | 2014-11-13 | アンジェスMg株式会社 | Oral vaccine having improved cell-mediated immunity induction potency |
WO2015031778A2 (en) | 2013-08-30 | 2015-03-05 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of tuberculosis |
WO2015103602A1 (en) * | 2014-01-06 | 2015-07-09 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
US10166195B2 (en) | 2014-03-05 | 2019-01-01 | Orbis Health Solutions, Llc | Vaccine delivery systems using yeast cell wall particles |
CN113419058A (en) | 2014-04-11 | 2021-09-21 | 全球免疫股份有限公司 | Yeast-based immunotherapy and type I interferon sensitivity |
CN105233302B (en) * | 2014-07-10 | 2018-10-19 | 中国人民解放军军事医学科学院生物工程研究所 | A kind of preparation method of influenza hemagglutinin glycopolypeptide multimer object nano particle |
CN107530383A (en) | 2015-01-09 | 2018-01-02 | 埃图比克斯公司 | Method and composition for research of Ebola vaccine inoculation |
US11020470B2 (en) * | 2015-04-13 | 2021-06-01 | The Regents Of The University Of Michigan | Virus-like particles |
KR20180054587A (en) | 2015-08-03 | 2018-05-24 | 글로브이뮨 | Modified yeast-brachyury immunotherapeutic composition |
EP3334455A4 (en) * | 2015-08-11 | 2019-08-21 | Orbis Health Solutions LLC | Bacterial and viral vaccine strategy |
GB2552441A (en) * | 2015-10-22 | 2018-01-31 | Royal Veterinary College | Methods |
EP3195878A1 (en) | 2016-01-22 | 2017-07-26 | Werner Lubitz | Bacterial ghosts for the treatment of cancer |
US11154597B2 (en) | 2016-03-24 | 2021-10-26 | Nantcell, Inc. | Sequence arrangements and sequences for neoepitope presentation |
CA3061240C (en) | 2017-04-24 | 2024-01-16 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
CN111556896A (en) | 2017-12-21 | 2020-08-18 | 株式会社绿色生物医药 | Cross immunity antigen vaccine and its preparation method |
DE102017012109A1 (en) | 2017-12-27 | 2019-06-27 | Martin-Luther-Universität Halle-Wittenberg | Optimized host / vector system for the generation of protective mono- and multivalent subunit vaccines based on the yeast Kluyveromyces lactis |
US20210154250A1 (en) * | 2018-05-15 | 2021-05-27 | Globeimmune, Inc. | Lysates of recombinant yeast for inducing cellular immune responses |
JP7320601B2 (en) * | 2018-09-11 | 2023-08-03 | 上▲海▼市公共▲衛▼生▲臨▼床中心 | Broad-spectrum anti-influenza vaccine immunogen and its use |
US20210290708A1 (en) | 2018-09-21 | 2021-09-23 | Nantcell, Inc. | Methods and compositions for modulating myeloid-derived suppressor cells |
AU2020279381A1 (en) * | 2019-05-21 | 2021-12-09 | Esperovax Inc. | Yeast-based oral vaccination |
WO2021163222A1 (en) * | 2020-02-11 | 2021-08-19 | Cytonus Therapeutics, Inc. | Rapid vaccine platform |
US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
WO2021211691A1 (en) | 2020-04-14 | 2021-10-21 | Immunitybio, Inc. | Yeast lysate covid-19 vaccine |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
US5830463A (en) * | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
CA2180965C (en) * | 1994-01-11 | 2010-05-11 | Tom Maria Deroo | Influenza vaccine |
US5691189A (en) * | 1994-01-19 | 1997-11-25 | Bristol-Myers Squibb Company | Saccharomyces cerevisiae expressing M2 protein of influenza A virus |
US6696251B1 (en) * | 1996-05-31 | 2004-02-24 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US20020044948A1 (en) * | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
CA2410297C (en) * | 2000-06-23 | 2011-03-15 | American Cyanamid Company | Assembly of wild-type and chimeric influenza virus-like particles (vlps) |
US7083787B2 (en) * | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
US20030008000A1 (en) * | 2001-03-08 | 2003-01-09 | Wong Jonathan P. | DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus |
US20030202982A1 (en) * | 2001-08-15 | 2003-10-30 | Birkett Ashley J. | Influenza immunogen and vaccine |
WO2004058157A2 (en) | 2002-12-16 | 2004-07-15 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
US7439042B2 (en) * | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
US8592197B2 (en) * | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
AU2005248361B2 (en) * | 2004-05-18 | 2010-03-11 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
JP5302537B2 (en) * | 2004-09-17 | 2013-10-02 | ユニバーシティ オブ マサチューセッツ | Compositions for lysosomal enzyme deficiency and their use |
TW201412329A (en) * | 2006-02-02 | 2014-04-01 | Globeimmune Inc | Yeast-based vaccine for inducing an immune response |
-
2007
- 2007-02-02 TW TW102144486A patent/TW201412329A/en unknown
- 2007-02-02 CN CN201510122553.9A patent/CN104826102A/en not_active Withdrawn
- 2007-02-02 SG SG201100779-6A patent/SG169375A1/en unknown
- 2007-02-02 US US11/670,902 patent/US7736642B2/en not_active Expired - Fee Related
- 2007-02-02 KR KR20087020923A patent/KR101492524B1/en active IP Right Grant
- 2007-02-02 JP JP2008553534A patent/JP5198290B2/en not_active Expired - Fee Related
- 2007-02-02 MX MX2008009929A patent/MX2008009929A/en active IP Right Grant
- 2007-02-02 IN IN8830DEN2014 patent/IN2014DN08830A/en unknown
- 2007-02-02 AU AU2007212076A patent/AU2007212076B2/en not_active Ceased
- 2007-02-02 CN CN200780009861.4A patent/CN101405026B/en not_active Expired - Fee Related
- 2007-02-02 CA CA002638815A patent/CA2638815A1/en not_active Withdrawn
- 2007-02-02 SG SG10201402236VA patent/SG10201402236VA/en unknown
- 2007-02-02 WO PCT/US2007/061572 patent/WO2007092792A2/en active Application Filing
- 2007-02-02 EP EP07717549A patent/EP1988919A4/en not_active Withdrawn
- 2007-02-02 EP EP11180828.3A patent/EP2468296A3/en not_active Withdrawn
- 2007-02-02 KR KR1020147004408A patent/KR20140029551A/en not_active Application Discontinuation
- 2007-02-02 BR BRPI0706913-8A patent/BRPI0706913A2/en not_active Application Discontinuation
- 2007-02-02 TW TW096103976A patent/TW200806316A/en unknown
-
2008
- 2008-07-31 IL IL193196A patent/IL193196A/en active IP Right Review Request
-
2010
- 2010-04-16 US US12/762,221 patent/US20100196411A1/en not_active Abandoned
-
2012
- 2012-11-29 JP JP2012260860A patent/JP2013075899A/en active Pending
-
2014
- 2014-05-08 IL IL232518A patent/IL232518A0/en unknown
- 2014-11-13 JP JP2014230982A patent/JP2015038147A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2015038147A (en) | 2015-02-26 |
TW201412329A (en) | 2014-04-01 |
MX2008009929A (en) | 2008-10-01 |
JP2009528987A (en) | 2009-08-13 |
US20100196411A1 (en) | 2010-08-05 |
EP1988919A2 (en) | 2008-11-12 |
IL232518A0 (en) | 2014-06-30 |
IN2014DN08830A (en) | 2015-07-10 |
CA2638815A1 (en) | 2007-08-16 |
EP2468296A3 (en) | 2013-12-04 |
CN101405026B (en) | 2015-04-22 |
JP2013075899A (en) | 2013-04-25 |
IL193196A (en) | 2015-01-29 |
KR101492524B1 (en) | 2015-02-12 |
CN101405026A (en) | 2009-04-08 |
US20080003239A1 (en) | 2008-01-03 |
WO2007092792A2 (en) | 2007-08-16 |
KR20080089671A (en) | 2008-10-07 |
TW200806316A (en) | 2008-02-01 |
EP2468296A2 (en) | 2012-06-27 |
JP5198290B2 (en) | 2013-05-15 |
KR20140029551A (en) | 2014-03-10 |
BRPI0706913A2 (en) | 2011-04-12 |
WO2007092792A3 (en) | 2008-02-28 |
AU2007212076B2 (en) | 2012-10-18 |
IL193196A0 (en) | 2011-08-01 |
AU2007212076A1 (en) | 2007-08-16 |
EP1988919A4 (en) | 2009-06-10 |
CN104826102A (en) | 2015-08-12 |
SG169375A1 (en) | 2011-03-30 |
US7736642B2 (en) | 2010-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL232518A0 (en) | Yeast-based vaccine for inducing an immune response | |
GB0607088D0 (en) | Vaccine | |
PL2173376T3 (en) | Multimeric multiepitope influenza vaccines | |
EP2062246A4 (en) | Chimeric virus vaccines | |
EP2056861A4 (en) | Vaccine immunotherapy | |
EP2205256A4 (en) | Reagents for inducing an immune response | |
GB0616306D0 (en) | Vaccines | |
EP2213301A4 (en) | Immune response inducer | |
ZA201001029B (en) | Vaccines | |
EP1998814A4 (en) | Novel influenza m2 vaccines | |
EP1970074A4 (en) | Immune adjuvant | |
HK1129836A1 (en) | Ipv-dpt vaccine ipv-dpt | |
EP2114416A4 (en) | Method of inducing an immune response | |
GB0614460D0 (en) | Vaccines | |
ZA200901592B (en) | Vaccine | |
GB0625593D0 (en) | Vaccine | |
GB0620175D0 (en) | Vaccines | |
GB0620160D0 (en) | Vaccines | |
GB0614473D0 (en) | Vaccines | |
GB0615115D0 (en) | Vaccines | |
GB0601733D0 (en) | Vaccines | |
GB0621785D0 (en) | Vaccines | |
GB0614254D0 (en) | Vaccine | |
GB0608962D0 (en) | Vaccine | |
GB0606256D0 (en) | Anti-atheroma vaccine |